Ovarian Cancer and Glutamine Metabolism

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 Mar 11

PMID 36902470

Authors

Zacharias Fasoulakis

Antonios Koutras

Thomas Ntounis

Ioannis Prokopakis

Paraskevas Perros

Athanasios Chionis

Ioakeim Sapantzoglou

Alexandros Katrachouras

Kyriakos Konis

Athina A Samara

Asimina Valsamaki

Vasileios-Chrysovalantis Palios

Panagiotis Symeonidis

Konstantinos Nikolettos

Athanasios Pagkalos

Sotirios Sotiriou

Marianna Theodora

Panos Antsaklis

Georgios Daskalakis

Emmanuel N Kontomanolis

Affiliations

Soon will be listed here.

Abstract

Cancer cells are known to have a distinct metabolic profile and to exhibit significant changes in a variety of metabolic mechanisms compared to normal cells, particularly glycolysis and glutaminolysis, in order to cover their increased energy requirements. There is mounting evidence that there is a link between glutamine metabolism and the proliferation of cancer cells, demonstrating that glutamine metabolism is a vital mechanism for all cellular processes, including the development of cancer. Detailed knowledge regarding its degree of engagement in numerous biological processes across distinct cancer types is still lacking, despite the fact that such knowledge is necessary for comprehending the differentiating characteristics of many forms of cancer. This review aims to examine data on glutamine metabolism and ovarian cancer and identify possible therapeutic targets for ovarian cancer treatment.

Citing Articles

Branched-chain amino acid catabolism promotes ovarian cancer cell proliferation via phosphorylation of mTOR.

Lusk H, Haughan M, Bergsten T, Burdette J, Sanchez L bioRxiv. 2024; .

PMID: 39464074 PMC: 11507863. DOI: 10.1101/2024.10.15.618560.

Metabolomic Analysis of Histological Composition Variability of High-Grade Serous Ovarian Cancer Using H HR MAS NMR Spectroscopy.

Skorupa A, Klimek M, Ciszek M, Pakulo S, Cichon T, Cichon B Int J Mol Sci. 2024; 25(20).

PMID: 39456684 PMC: 11507550. DOI: 10.3390/ijms252010903.

NEK6 dampens FOXO3 nuclear translocation to stabilize C-MYC and promotes subsequent de novo purine synthesis to support ovarian cancer chemoresistance.

Liu J, Wang H, Wan H, Yang J, Gao L, Wang Z Cell Death Dis. 2024; 15(9):661.

PMID: 39256367 PMC: 11387829. DOI: 10.1038/s41419-024-07045-2.

Molecular mechanisms of cisplatin resistance in ovarian cancer.

Jiang C, Shen C, Ni M, Huang L, Hu H, Dai Q Genes Dis. 2024; 11(6):101063.

PMID: 39224110 PMC: 11367050. DOI: 10.1016/j.gendis.2023.06.032.

Glutamine metabolism prognostic index predicts tumour microenvironment characteristics and therapeutic efficacy in ovarian cancer.

Gao L, Wei Z, Ying F, Huang L, Zhang J, Sun S J Cell Mol Med. 2024; 28(7):e18198.

PMID: 38506093 PMC: 10951877. DOI: 10.1111/jcmm.18198.

References

Hatipoglu A, Menon D, Levy T, Frias M, Foster D . Inhibiting glutamine utilization creates a synthetic lethality for suppression of ATP citrate lyase in KRas-driven cancer cells. PLoS One. 2022; 17(10):e0276579. PMC: 9586366. DOI: 10.1371/journal.pone.0276579. View

Rooth C . Ovarian cancer: risk factors, treatment and management. Br J Nurs. 2013; 22(17):S23-30. DOI: 10.12968/bjon.2013.22.Sup17.S23. View

Willems L, Jacque N, Jacquel A, Neveux N, Trovati Maciel T, Lambert M . Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia. Blood. 2013; 122(20):3521-32. PMC: 3829119. DOI: 10.1182/blood-2013-03-493163. View

Fu Y, Lin H, Liu X, Fang W, Meadows G . Cell death of prostate cancer cells by specific amino acid restriction depends on alterations of glucose metabolism. J Cell Physiol. 2010; 224(2):491-500. DOI: 10.1002/jcp.22148. View

Sung P, Chang Y, Chao K, Chuang C . Global distribution pattern of histological subtypes of epithelial ovarian cancer: a database analysis and systematic review. Gynecol Oncol. 2014; 133(2):147-54. DOI: 10.1016/j.ygyno.2014.02.016. View

Kajiyama H, Shibata K, Mizuno M, Umezu T, Suzuki S, Yamamoto E . Long-term clinical outcome of patients with recurrent epithelial ovarian carcinoma: is it the same for each histological type?. Int J Gynecol Cancer. 2012; 22(3):394-9. DOI: 10.1097/IGC.0b013e31823eed2c. View

Simpson N, Tryndyak V, Pogribna M, Beland F, Pogribny I . Modifying metabolically sensitive histone marks by inhibiting glutamine metabolism affects gene expression and alters cancer cell phenotype. Epigenetics. 2012; 7(12):1413-20. PMC: 3528696. DOI: 10.4161/epi.22713. View

Siegel R, Ma J, Zou Z, Jemal A . Cancer statistics, 2014. CA Cancer J Clin. 2014; 64(1):9-29. DOI: 10.3322/caac.21208. View

Cluntun A, Lukey M, Cerione R, Locasale J . Glutamine Metabolism in Cancer: Understanding the Heterogeneity. Trends Cancer. 2017; 3(3):169-180. PMC: 5383348. DOI: 10.1016/j.trecan.2017.01.005. View

10.

Phang J, Liu W, Hancock C . Bridging epigenetics and metabolism: role of non-essential amino acids. Epigenetics. 2013; 8(3):231-6. PMC: 3669115. DOI: 10.4161/epi.24042. View

11.

Wu S, Fukumoto T, Lin J, Nacarelli T, Wang Y, Ong D . Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma. Nat Cancer. 2021; 2(2):189-200. PMC: 8168620. DOI: 10.1038/s43018-020-00160-x. View

12.

Koochekpour S, Majumdar S, Azabdaftari G, Attwood K, Scioneaux R, Subramani D . Serum glutamate levels correlate with Gleason score and glutamate blockade decreases proliferation, migration, and invasion and induces apoptosis in prostate cancer cells. Clin Cancer Res. 2012; 18(21):5888-901. PMC: 3492499. DOI: 10.1158/1078-0432.CCR-12-1308. View

13.

Kim G, Lee D, Jeon Y, Yoo J, Kim S, Lee S . Glutamine Synthetase as a Therapeutic Target for Cancer Treatment. Int J Mol Sci. 2021; 22(4). PMC: 7915753. DOI: 10.3390/ijms22041701. View

14.

Tian Y, Du W, Cao S, Wu Y, Dong N, Wang Y . Systematic analyses of glutamine and glutamate metabolisms across different cancer types. Chin J Cancer. 2017; 36(1):88. PMC: 5678792. DOI: 10.1186/s40880-017-0255-y. View

15.

Kobayashi H, Imanaka S, Shigetomi H . Revisiting therapeutic strategies for ovarian cancer by focusing on redox homeostasis. Oncol Lett. 2022; 23(3):80. PMC: 8771630. DOI: 10.3892/ol.2022.13200. View

16.

Trachootham D, Alexandre J, Huang P . Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?. Nat Rev Drug Discov. 2009; 8(7):579-91. DOI: 10.1038/nrd2803. View

17.

Guo J, Satoh K, Tabata S, Mori M, Tomita M, Soga T . Reprogramming of glutamine metabolism via glutamine synthetase silencing induces cisplatin resistance in A2780 ovarian cancer cells. BMC Cancer. 2021; 21(1):174. PMC: 7891143. DOI: 10.1186/s12885-021-07879-5. View

18.

Shen Y, Hong J, Asaka R, Asaka S, Hsu F, Suryo Rahmanto Y . Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers. Cancer Res. 2020; 80(20):4514-4526. PMC: 7572606. DOI: 10.1158/0008-5472.CAN-19-3971. View

19.

Leippe D, Sobol M, Vidugiris G, Cali J, Vidugiriene J . Bioluminescent Assays for Glucose and Glutamine Metabolism: High-Throughput Screening for Changes in Extracellular and Intracellular Metabolites. SLAS Discov. 2016; 22(4):366-377. DOI: 10.1177/1087057116675612. View

20.

Yuan L, Sheng X, Willson A, Roque D, Stine J, Guo H . Glutamine promotes ovarian cancer cell proliferation through the mTOR/S6 pathway. Endocr Relat Cancer. 2015; 22(4):577-91. PMC: 4500469. DOI: 10.1530/ERC-15-0192. View